WO2014035070A1 - 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 - Google Patents

피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2014035070A1
WO2014035070A1 PCT/KR2013/006985 KR2013006985W WO2014035070A1 WO 2014035070 A1 WO2014035070 A1 WO 2014035070A1 KR 2013006985 W KR2013006985 W KR 2013006985W WO 2014035070 A1 WO2014035070 A1 WO 2014035070A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
pyrazol
propyl
phenyl
kidney disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2013/006985
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
배윤수
하헌주
이기인
송경희
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ewha Womans University
Original Assignee
Ewha Womans University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Womans University filed Critical Ewha Womans University
Priority to PL13834243T priority Critical patent/PL2889032T3/pl
Priority to ES13834243T priority patent/ES2734264T3/es
Priority to CN201380056244.5A priority patent/CN104755077B/zh
Priority to EP13834243.1A priority patent/EP2889032B1/en
Priority to US14/424,771 priority patent/US10047067B2/en
Priority to JP2015529664A priority patent/JP5974180B2/ja
Publication of WO2014035070A1 publication Critical patent/WO2014035070A1/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to a composition for preventing or treating kidney disease comprising a pyrazole derivative.
  • Chronic kidney disease is a serious disease in which the incidence and mortality rate of cardiovascular disease is 10 times higher than the age-control group, and the number of patients suffering from this disease has increased exponentially in recent years (Schieppati A, Remuzzi G: Chronic renal). diseases as a public health problem: epidemiology, social, and economic implications.Kidney Int Suppl. 98: S7-S10, 2005 (1)).
  • Chronic renal disease is characterized by epithelial-to-mesenchymal transition (EMT) and accumulation of extracellular matrix (ECM) proteins.
  • EMT epithelial-to-mesenchymal transition
  • ECM extracellular matrix
  • Typical pathological findings include glomerular capillary basal membrane thickening, vascular epilepsy, and tubular epilepsy.
  • Fibrosis hypertrophy of glomeruli and kidneys, and proteinuria.
  • Transforming growth factor- ⁇ 1 (TGF- ⁇ 1) a factor involved in renal tissue fibrosis, is recognized as an indicator of fibrosis as a final mediator of the production of extracellular matrix protein by various stimuli (Qian Y, Feldman).
  • E Pennathur S, Kretzler M, Brosius FC 3rd: From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy.Diabetes. 57: 1439-45, 2008)
  • Diabetic kidney disease is one of the most common causes of end-stage renal disease (ESRD) (US Renal Data System, USRDS 2011 Annual Data Report: Atlas of End). Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011).
  • ESRD end-stage renal disease
  • the present inventors have found that the pyrazole derivatives of the present invention have an effect of reducing proteinuria, decreasing glomerular intervascular cell formation, and inhibiting renal fibrosis, thereby completing the present invention by confirming that they can be used for the prevention or treatment of kidney disease. It was.
  • An object of the present invention is to provide a composition for preventing or treating kidney disease comprising a pyrazole derivative.
  • Another object of the present invention is to provide a method for preventing or treating kidney disease by administering a pyrazole derivative of the present invention and the use of the pyrazole derivative of the present invention for preparing a pharmaceutical formulation for preventing or treating kidney disease. will be.
  • the present invention provides a composition for preventing or treating kidney disease, comprising a compound selected from the compounds listed below or a pharmaceutically acceptable salt thereof:
  • the present invention provides a composition for preventing or treating kidney disease, comprising a compound selected from the compounds listed below or a pharmaceutically acceptable salt thereof:
  • pharmaceutically acceptable salts mean salts commonly used in the pharmaceutical industry, for example, inorganic acid salts prepared with hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid, tartaric acid, sulfuric acid, and the like, Acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid Sulfonic acid salts prepared with organic acid salts, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, and the like, aspartic acid, ascorbic acid
  • kidney disease may include diabetic nephropathy, hypertensive nephropathy, glomerulonephritis, pyelonephritis, interstitial nephritis, lupus nephritis, polycystic kidney disease or renal failure
  • the kidney disease may be characterized by proteinuria, glomerulosclerosis, renal interstitial fibrosis and the like.
  • composition of the present invention may include pharmaceutically acceptable additives such as pharmaceutically acceptable diluents, binders, disintegrants, lubricants, pH adjusting agents, antioxidants, dissolution aids, etc. without departing from the effects of the present invention.
  • pharmaceutically acceptable additives such as pharmaceutically acceptable diluents, binders, disintegrants, lubricants, pH adjusting agents, antioxidants, dissolution aids, etc. without departing from the effects of the present invention.
  • the diluent may be sugar, starch, microcrystalline cellulose, lactose (lactose monohydrate), glucose, di-mannitol, alginate, alkaline earth metal salts, clay, polyethylene glycol, anhydrous calcium hydrogen phosphate, or a mixture thereof; Binders are starch, microcrystalline cellulose, highly dispersible silica, mannitol, di-mannitol, sucrose, lactose monohydrate, polyethylene glycol, polyvinylpyrrolidone (povidone), polyvinylpyrrolidone copolymer (copovidone), hypromellose , Hydroxypropyl cellulose, natural gum, synthetic gum, copovidone, gelatin, or a mixture thereof.
  • Binders are starch, microcrystalline cellulose, highly dispersible silica, mannitol, di-mannitol, sucrose, lactose monohydrate, polyethylene glycol, polyvinylpyrrolidone (povidone
  • the disintegrating agent may be a starch or modified starch such as sodium starch glycolate, corn starch, potato starch or pregelatinized starch; Clay such as bentonite, montmorillonite, or veegum; Celluloses such as microcrystalline cellulose, hydroxypropyl cellulose or carboxymethyl cellulose; Algins such as sodium alginate or alginic acid; Crosslinked celluloses such as croscarmellose sodium; Gums such as guar gum and xanthan gum; Crosslinked polymers such as crosslinked polyvinylpyrrolidone (crospovidone); Effervescent agents such as sodium bicarbonate, citric acid, or mixtures thereof can be used.
  • Clay such as bentonite, montmorillonite, or veegum
  • Celluloses such as microcrystalline cellulose, hydroxypropyl cellulose or carboxymethyl cellulose
  • Algins such as sodium alginate or alginic acid
  • Crosslinked celluloses such as croscarmel
  • Lubricants include talc, stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulfate, hydrogenated vegetable oils, sodium benzoate, sodium stearyl fumarate, glyceryl behenate, glyceryl monorate, glyceryl monostearate, glyceryl palmi Tostearate, colloidal silicon dioxide, mixtures thereof, and the like.
  • pH adjusters include acidifying agents such as acetic acid, adipic acid, ascorbic acid, sodium ascorbate, sodium ether, malic acid, succinic acid, tartaric acid, fumaric acid, citric acid (citric acid) and precipitated calcium carbonate, ammonia water, meglumine, carbonate Basic agents, such as sodium, magnesium oxide, magnesium carbonate, sodium citrate, and calcium tribasic phosphate, etc. can be used.
  • acidifying agents such as acetic acid, adipic acid, ascorbic acid, sodium ascorbate, sodium ether, malic acid, succinic acid, tartaric acid, fumaric acid, citric acid (citric acid) and precipitated calcium carbonate, ammonia water, meglumine, carbonate
  • Basic agents such as sodium, magnesium oxide, magnesium carbonate, sodium citrate, and calcium tribasic phosphate, etc. can be used.
  • the antioxidant may be dibutyl hydroxy toluene, butylated hydroxyanisole, tocopherol acetate, tocopherol, propyl gallate, sodium hydrogen sulfite, sodium pyrosulfite, etc.
  • the dissolution aid is Polyoxyethylene sorbitan fatty acid esters such as sodium lauryl sulfate and polysorbate, sodium docusate, poloxamer and the like.
  • the enteric polymer is insoluble or stable under acidic conditions of less than pH 5, and refers to a polymer that is dissolved or decomposed under specific pH conditions of pH 5 or higher.
  • enteric polymer for example, hypromellose acetate succinate and hypromellose phthalate.
  • the enteric acrylic acid copolymer Poly (methacrylate methyl methacrylate) copolymer (e.g. Eudragit L, Eudragit S, Evonik, Germany), poly (methacrylate acrylate) copolymer (e.g.
  • Eudragit L100- Enteric polymethacrylate copolymers such as 55); Vinyl acetate-maleic anhydride copolymer, styrene-maleic anhydride copolymer, styrene-maleic acid monoester copolymer, vinylmethyl ether-maleic anhydride copolymer, ethylene-maleic anhydride copolymer, vinylbutyl ether-maleic anhydride copolymer, acrylic Enteric maleic acid copolymers such as ronitrile-methyl methacrylate-maleic anhydride copolymer and butyl styrene-styrene-maleic anhydride copolymer; And enteric polyvinyl derivatives such as polyvinyl alcohol phthalate, polyvinyl acetal phthalate, polyvinyl butyrate phthalate and polyvinyl acetal phthalate.
  • the water insoluble polymer refers to a polymer that is not soluble in pharmaceutically acceptable water that controls the release of the drug.
  • the water insoluble polymer may be polyvinylacetate (e.g. colicoat SR30D), water insoluble polymethacrylate copolymer [e.g. poly (ethylacrylate-methyl methacrylate) copolymer (e.g.
  • Eudragit NE30D Poly (ethylacrylate-methyl methacrylate-trimethylaminoethyl methacrylate) copolymer (e.g., Eudragit RSPO), etc., ethyl cellulose, cellulose ester, cellulose ether, cellulose acylate, cellulose dicylate, Cellulose triacylate, cellulose acetate, cellulose diacetate and cellulose triacetate.
  • the hydrophobic compound refers to a substance that does not dissolve in pharmaceutically acceptable water that controls the release of the drug.
  • Fatty acids and fatty acid esters such as, for example, glyceryl palmitostearate, glyceryl stearate, glyceryl bihenate, cetyl palmitate, glyceryl monooleate and threric acid;
  • Fatty acid alcohols such as cetostearyl alcohol, cetyl alcohol and stearyl alcohol; Waxes such as carnauba wax, beeswax, and microcrystalline wax;
  • Inorganic materials such as talc, precipitated calcium carbonate, calcium dihydrogen phosphate, zinc oxide, titanium oxide, kaolin, bentonite, montmorillonite, and gum.
  • the hydrophilic polymer refers to a polymeric material that is dissolved in pharmaceutically acceptable water that controls the release of the drug.
  • Sugars such as, for example, dextrins, polydextrins, dextrans, pectins and pectin derivatives, alginates, polygalacturonic acids, xylans, arabinoxylans, arabinogalactans, starches, hydroxypropylstarches, amylose, and amylopectins ;
  • Cellulose derivatives such as hypromellose, hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, methyl cellulose and carboxymethyl cellulose sodium;
  • Gums such as guar gum, locust bean gum, tragacantha, carrageenan, acacia gum, gum arabic, gellan gum, and xanthan gum;
  • Proteins such as gelatin, casein, and zein;
  • Polyvinyl derivatives such as
  • Eudragit E100, Evonik, Germany poly (ethyl acrylate-methyl methacrylate- Hydrophilic polymethacrylate copolymers such as triethylaminoethyl- methacrylate chloride) copolymers (eg, Eudragit RL, RS, Evonik, Germany); Polyethylene derivatives such as polyethylene glycol, and polyethylene oxide; Carbomer and the like.
  • a pharmaceutically acceptable additive may be selected and used in the preparation of the present invention as various additives selected from colorants and fragrances.
  • the range of the additives is not limited to the use of the above additives, and the above-mentioned additives may be formulated by containing a dose in a normal range by selection.
  • compositions according to the invention can be used in the form of oral dosage forms, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppositories or sterile injectable solutions according to conventional methods. have.
  • the present invention also provides a method for preventing or treating kidney disease by administering to a subject including a mammal a composition for preventing or treating kidney disease comprising a compound selected from the compounds listed below of the present invention, or a pharmaceutically acceptable salt thereof. to provide:
  • the term “administration” means introducing a composition for preventing or treating kidney disease of the present invention to a patient by any suitable method, and the route of administration of the composition for preventing or treating kidney disease of the present invention reaches a target tissue.
  • administration may be via any general route.
  • composition for preventing or treating kidney disease according to the present invention may be administered once or twice a day at regular time intervals.
  • the dosage of a compound selected from the compounds listed below of the present invention, or a pharmaceutically acceptable salt thereof, depends on the weight, age, sex, health condition, diet, time of administration, method of administration, excretion rate and severity of the disease of the patient. The range varies:
  • the dosage is 0.1 to 100 mg / kg / day, which may vary depending on the severity, age, sex, etc. of the patient.
  • the present invention also provides a method for preventing or treating kidney disease by administering to a subject including a mammal a composition for preventing or treating kidney disease comprising a compound selected from the compounds listed below of the present invention, or a pharmaceutically acceptable salt thereof. to provide:
  • the invention also provides the use of the compounds listed below or their pharmaceutically acceptable salts for the preparation of pharmaceutical preparations for the prevention or treatment of kidney disease:
  • the invention also provides the use of the compounds listed below or their pharmaceutically acceptable salts for the preparation of pharmaceutical preparations for the prevention or treatment of kidney disease:
  • the compounds of the present invention or their pharmaceutically acceptable salts can be used for the prevention or treatment of kidney disease because of their ability to reduce proteinuria, reduce glomerular intervascular cell formation and inhibit renal fibrosis.
  • Example 1 is a diagram showing the effect of the compound of Example 1 on glomerular hypertrophy and glomerular vascular interstitial expansion.
  • FIG. 2 is a diagram showing the effect of the compound of Example 1 on collagen accumulation (Masson's trichrome staining, picrosirius red staining) and macrophage marker (F4 / 80) production.
  • FIG. 3 shows the effect of the compound of Example 1 on the production of transforming growth factor (TGF- ⁇ 1), extracellular matrix proteins (fibronectin, collagen IV and collagen I ⁇ 1) and inflammatory factors (F4 / 80) of the compound of Example 1 It is a diagram showing.
  • TGF- ⁇ 1 transforming growth factor
  • extracellular matrix proteins fibronectin, collagen IV and collagen I ⁇ 1
  • F4 / 80 inflammatory factors
  • Example 1 1- (pyridin-2-yl) -3-phenyl-4-propyl-1H-pyrazol-5-olHCl [1- (pyridin-2-yl) -3-phenyl-4-propyl -1H-pyrazol-5-olHCl] (hereinafter referred to as 18-278 compound)
  • Step 1 Preparation of 1- (pyridin-2-yl) -3-phenyl-4-propyl - 1H - pyrazol-5-ol [1- (pyridin-2-yl ) -3-phenyl-4-propyl- 1H - synthesis of pyrazol-5-ol]
  • Step 2 Synthesis of 1- (pyridin-2-yl) -3-phenyl-4-propyl- 1 H -pyrazol-5-olHCl (278)
  • the compound of Chemical Formula 3 was synthesized according to the synthesis method disclosed in Korean Patent No. 10-0942382. Specifically, 3- (3-methoxyphenyl) -3-oxo-propionic acid ethyl ester (1 equivalent) and 4 ml of ethanol were added to a round bottom flask, and 2-hydrazinopyridine (1.1 equivalent) was added to 3 ml of ethanol. Diluted and slowly added dropwise at 0 ° C. Heated to reflux for 20 minutes. After distillation under reduced pressure to remove the solvent, the resulting solid was washed with hexane and ethyl acetate and dried in vacuo to give the compound of formula 3 in a yield of 67%.
  • the compound of formula 3 and the compound of formula 3 ' have an enol type and keto type relationship. Therefore, the compound of formula 3 may also exist as a compound of formula 3 'by keto-enol tautomer reaction.
  • Example 4 3- (4-bromophenyl) -1- (pyridin-2-yl) -1H-pyrazol-5-yl acetate [3- (4-bromophenyl) -1- (pyridin-2-yl ) -1H-pyrazol-5-yl acetate] (hereinafter referred to as 18-067 compound)
  • Step 1 Synthesis of ethyl 4- (naphthalen-3-yloxy) -3-oxobutanoate [ethyl 4- (naphthalen-3-yloxy) -3-oxobutanoate
  • Step 2 Synthesis of 3-((naphthylene-3-yloxy) methyl) -1- (pyridin-2-yl) -1H-pyrazol-5-ol
  • the compound of Formula 8 was prepared according to the synthesis method disclosed in Korean Patent Laid-Open No. 10-2011-0025149.
  • a compound of formula 9 was prepared according to the synthesis method disclosed in Korean Patent Laid-Open No. 10-2011-0025149.
  • Example 9 3- ⁇ 2- (4-hydroxy-3-methoxyphenyl) vinyl ⁇ -4-propyl-1- (2-pyridinyl) pyrazole-5-ol [3- ⁇ 2- (4 -hydroxy-3-methoxyphenyl) vinyl ⁇ -4-propyl-1- (2-pyridinyl) pyrazol-5-ol] (hereinafter referred to as 18-273 compound)
  • the weight of the diabetic group (DM) was decreased and the blood sugar and hemoglobin A1c were increased in comparison with the control group (WT), indicating that hyperglycemia was maintained for 12 weeks after type 1 diabetes.
  • the height ratio of kidney weight and weight per body weight also increased, indicating that hypertrophy was observed.
  • Serum creatinine was not different from the control group, but albumin excretion was increased.
  • mice that induced diabetes and received 1- (pyridin-2-yl) -3-phenyl-4-propyl- 1H -pyrazol-5-ol.HCl which is a compound of Example 1 of the present invention
  • body weight, blood sugar, hemoglobin A1c, kidney weight, kidney weight per body weight, and blood creatinine showed no difference compared to the diabetic group, but albumin excretion was decreased.
  • the compound of the present invention (1- (pyridin-2-yl) -3-phenyl-4-propyl- 1H -pyrazol-5-olHCl) is a proteinuria (excretion of albumin) accompanied by diabetic nephropathy It was confirmed that it can have a kidney protective effect by reducing the.
  • Example 11 Confirmation of glomerular hypertrophy and glomerular intervascular cell formation
  • Example 1 1- (pyridin-2-yl) -3-phenyl-4-propyl- 1H -pyrazol-5-ol.HCl which causes diabetes according to the method disclosed in Example 10 and is a compound of Example 1 of the present invention
  • PBS phosphate-buffered saline
  • PLP paraformaldehyde-lysine-periodate
  • FIG. 1 A is a photograph showing glomeruli stained with PAS (periodic acid-Schiff), B is a graph showing glomerular volume, and C is a graph showing a fractional mesangial area.
  • the control group (WT), the diabetic group (DM), and the compound treated group of Example 1 are respectively the type 1 diabetes-induced group, the type 1 diabetes-induced group, and the type 1 diabetes-induced group. It means the compound treatment group of Example 1.
  • the data in FIG. 1 is mean ⁇ standard error (SE) of 8-12 mice per group.
  • SE standard error
  • Statistical comparisons between groups were tested by analysis of variance (ANOVA) and Fisher's least significant difference method. It was judged that only the value whose P value was less than 0.05 was meaningful.
  • Example 2 As shown in Table 2, the compound-administered group of Example 1 of the present invention increased the glomerular size compared to the control group, but significantly decreased compared to the diabetic group, and glomerular vascular cell formation tended to decrease to the control level compared to the diabetic group. Showed.
  • the compounds of the present invention are in renal proximal tubule cells Extracellular matrix It was confirmed that renal fibrosis can be suppressed by reducing collagen I ⁇ 1 expression and inhibiting collagen accumulation in tubular epilepsy.
  • the compound of the present invention (1- (pyridin-2-yl) -3-phenyl-4-propyl- 1H -pyrazol-5-ol.HCl) has a glomerular size and glomeruli in an animal model in which diabetic nephropathy is induced. It was confirmed that it may have a renal protective effect by reducing the formation of intervascular cells.
  • Example 12 Inhibiting Collagen Accumulation and Reducing Macrophage Reduction
  • Example 1 a compound of Example 1 of the present invention that induces diabetes according to the method disclosed in Example 11 Twelve weeks after treatment with all-HCl, cardiac perfusion with 0.1 M PBS (phosphate-buffered saline) was performed, and the tissue was fixed overnight with 2% PLP (paraformaldehyde-lysine-periodate).
  • PBS phosphate-buffered saline
  • the reaction was performed with a perox idase blocking reagent (Peroxidase Blocking Reagent Ready-To-Use from Dakocytomation) for 30 minutes, and a protein block serum-free solution (Protein Blocking Serum-Free Ready-To- from Dakocytomation).
  • a primary antibody F4 / 80 of Santa Cruz
  • ABC avidin-biotin-enzyme complex
  • Immunohistochemical staining IHC F4 / 80
  • Masson's trichrome and picrosirius red staining results are shown in FIG. 2.
  • the control group (WT), the diabetic group (DM), and the compound treated group of Example 1 are the type 1 diabetes-induced group, the type 1 diabetes-induced group, and the type 1 diabetes-induced group, respectively. It means the compound treatment group of Example 1.
  • black shows F 4/80 expressed in the drawing corresponding to IHC F4 / 80, and blue in the drawing corresponding to Masson's trichrome and picrosirius red, respectively.
  • red color show collagen expression.
  • Masson's trichrome staining showed that the diabetic group had a lot of blue staining sites compared to the control group. In addition, Masson's trichrome staining, it was confirmed that the compound treated group of Example 1 is reduced in the blue stained area as compared to the diabetic group. In the case of picrosirius red staining, the diabetic group was found to have more red stained spots than the control group. In addition, when the picrosirius red staining, it was confirmed that the compound treated group of Example 1 was reduced in red stained area as compared to the diabetic group.
  • Immunohistochemical staining (F4 / 80) was lower than the control group (F4 / 80), the diabetic group was found to have a lot of black staining site. In addition, when immunohistochemical staining (F4 / 80), it was confirmed that the compound treated group of Example 1 is reduced in black stained area compared to the diabetic group.
  • the compound of the present invention (1- (pyridin-2-yl) -3-phenyl-4-propyl- 1H -pyrazol-5-ol.HCl) inhibits collagen accumulation in animal models of diabetic nephropathy. And by reducing the macrophages (F4 / 80) it was confirmed that can have a kidney protective effect.
  • 1- (pyridin-2-yl) -3-phenyl-4-propyl- 1H -pyrazol-5- is a compound of Example 1 which induces diabetes and is according to the method disclosed in Example 10. Twelve weeks after all-HCl treatment, the supernatant was separately collected by centrifugation (13,000 rpm, 10 minutes) after crushing the tissue by administering Trizol solution (Invitrogen) in a designated amount (500 ⁇ l) to the renal tissue obtained by sacrifice. . 200 ⁇ l of chloroform was added and reacted for 15 minutes, followed by centrifugation. The collected total RNA was precipitated with isopropyl alchol and washed with 75% ethyl alcohol and used for the experiment.
  • Trizol solution Invitrogen
  • A is the ratio of TGF- ⁇ 1 mRNA expression to 18S rRNA
  • B is the ratio of fibronectin mRNA expression to 18S rRNA
  • C is the ratio of collagen IV mRNA expression to 18S rRNA
  • D is to 18S rRNA Collagen I ⁇ 1 mRNA expression ratio
  • E for graph are graphs showing the ratio of F4 / 80 mRNA expression for 18S rRNA.
  • the control group (WT), the diabetic group (DM), and the compound treated group of Example 1 are the type 1 diabetes-induced group, the type 1 diabetes-induced group, and the type 1 diabetes-induced group, respectively. It means the compound treatment group of Example 1.
  • Example 1 As shown in FIG. 3, 1- (pyridin-2-yl) -3-phenyl-4-propyl- 1H -pyrazol-5-ol.HCl, which causes diabetes and is a compound of Example 1 of the present invention, is administered.
  • TGF- ⁇ 1 a factor involved in renal fibrosis, fibronectin, collagen I ⁇ 1 and collagen IV, an inflammatory factor, well known as an extracellular matrix protein, F4 / 80
  • the amount of expression tended to decrease significantly compared to the diabetic group.
  • the compound (1- (pyridin-2-yl) -3-phenyl-4-propyl- 1H -pyrazol-5-ol.HCl) of the present invention may have a renal protective effect by inhibiting renal fibrosis. I could confirm it.
  • MProx24 a renal proximal tubule cell derived from the microfractured adult rat proximal tubule segment of the C57BL6 / J adult rat kidney, was supplied by Professor Sugaya of Mariana Medical University, Kanazawa Prefecture, Japan.
  • mProx24 was treated with 5% CO 2 at 37 ° C. in Dulbecco's modified Eagle's medium (DMEM) containing 10% neonatal serum (FCS; Gibco), 100 U / ml penicillin, 100 ⁇ g / ml streptomycin, and 44 mM NaHCO 3. Incubated at. Cells were cultured in 6-well plates to measure the level of RNA expression.
  • DMEM Dulbecco's modified Eagle's medium
  • FCS neonatal serum
  • DMEM medium containing 0.15% neonatal serum (FCS; Gibco)
  • FCS neonatal serum
  • Compounds of Examples 1 to 9 and Comparative Compounds were dissolved in DMSO (dimethylsulfoxide) at 50 mM, and serially diluted to 10 mM, 1 mM, 0.1 mM, and 0.01 mM.
  • mRNA expression was measured by real-time PCR using StepOnePlus (Applied Biosystems) with 20 ⁇ L reaction volume consisting of cDNA transcripts, primer pairs, and SYBR Green PCR Master Mix (Applied Biosystems). Condition: 95 °C 10 minutes ⁇ Repeat 15 seconds at 95 °C for 1 minute at 95 °C with denaturation process, 40 times 1 minute at 60 °C with primer annealing process ⁇ 15 seconds at 95 °C, 1 minute at 60 °C, 95 °C to measure melting curve 15 seconds). Quantification was normalized to 18S rRNA expression level.
  • the sequence of the mouse collagen I ⁇ 1 primer pair was 5'-GAACATCACCTACCACTGCA-3 '(SEQ ID NO: 13) and 5'-GTTGGGATGGAGGGAGTTTA-3' (SEQ ID NO: 14).
  • the mouse r18S rRNA forward primer sequence was 5′-CGA AAG CAT TTG CCA AGA AT-3 ′ (SEQ ID NO: 11), and the reverse primer sequence was 5′-AGT CGG CAT CGT TTA TGG TC-3 ′ (SEQ ID NO: 12).
  • Tables 3 and 12 to 4 to 13 show the effect of collagen I ⁇ 1 inhibition in renal proximal tubule cells by the compounds of Examples 1-9 and the compounds of Comparative Example 1, respectively.
  • Tables 3-12 and FIGS. 4-13 are the results of three to five replicates for each concentration.
  • the data of Tables 3 to 12 and FIGS. 4 to 14 are expressed as mean ⁇ standard error (SE).
  • SE standard error
  • Statistical comparisons between groups were tested by analysis of variance (ANOVA) and Fisher's least significant difference method. It was judged that only the value whose P value was less than 0.05 was meaningful. * P ⁇ 0.05 vs WT, ⁇ P ⁇ 0.05 vs DM
  • Tables 3 to 12 show the mean of the ratio of the amount of expression of collagen I ⁇ 1 (Col1 ⁇ ) to the amount of 18S rRNA expression (18S) of each group, the percentage of inhibition of expression of collagen I ⁇ 1, and the IC 50 value ( ⁇ M). Indicates.
  • the inhibition rate is 100% of the control group, hTGF- ⁇ 1 treatment and the relative inhibition rate when the inhibition rate of the compound according to the embodiment of the present invention or the compound according to the comparative example (TGF- ⁇ 1) is 0% it means.
  • IC of a compound according to an embodiment of the present invention 50 At least three times lower than the extracellular matrix It was confirmed that the expression level of collagen I ⁇ 1 (Col1 ⁇ ) can be more effectively reduced.
  • the compounds of the present invention are found in renal proximal tubule cells Extracellular matrix It was confirmed that renal fibrosis can be suppressed by reducing collagen I ⁇ 1 expression and inhibiting collagen accumulation in tubular epilepsy.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/KR2013/006985 2012-08-27 2013-08-02 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 Ceased WO2014035070A1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL13834243T PL2889032T3 (pl) 2012-08-27 2013-08-02 Kompozycja zawierająca pochodną pirazolu do zapobiegania lub leczenia choroby nerek
ES13834243T ES2734264T3 (es) 2012-08-27 2013-08-02 Composición para prevenir o tratar enfermedad renal que comprende derivado de pirazol
CN201380056244.5A CN104755077B (zh) 2012-08-27 2013-08-02 用于预防或治疗肾脏疾病的包含吡唑衍生物的组合物
EP13834243.1A EP2889032B1 (en) 2012-08-27 2013-08-02 Composition for preventing or treating kidney disease comprising pyrazole derivative
US14/424,771 US10047067B2 (en) 2012-08-27 2013-08-02 Composition for treating kidney disease comprising pyrazole derivative
JP2015529664A JP5974180B2 (ja) 2012-08-27 2013-08-02 ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120093936A KR101633957B1 (ko) 2012-08-27 2012-08-27 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
KR10-2012-0093936 2012-08-27

Publications (1)

Publication Number Publication Date
WO2014035070A1 true WO2014035070A1 (ko) 2014-03-06

Family

ID=50183832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/006985 Ceased WO2014035070A1 (ko) 2012-08-27 2013-08-02 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물

Country Status (9)

Country Link
US (1) US10047067B2 (enExample)
EP (1) EP2889032B1 (enExample)
JP (1) JP5974180B2 (enExample)
KR (1) KR101633957B1 (enExample)
CN (1) CN104755077B (enExample)
ES (1) ES2734264T3 (enExample)
PL (1) PL2889032T3 (enExample)
TR (1) TR201909923T4 (enExample)
WO (1) WO2014035070A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2754255C2 (ru) * 2017-04-20 2021-08-31 Аптабайо Терапьютикс Инк. Новое кристаллическое твердое соединение гидрохлорида 3-фенил-4-пропил-1-(пиридин-2-ил)-1н-пиразол-5-ола

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101826208B1 (ko) 2016-02-05 2018-02-06 경북대학교 산학협력단 뉴로펩타이드 y를 유효성분으로 포함하는, 신장질환의 예방 또는 치료용 약학적 조성물
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
WO2021101344A1 (ko) 2019-11-21 2021-05-27 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물
KR102277665B1 (ko) * 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
US20230201179A1 (en) * 2020-04-08 2023-06-29 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
CN115427039B (zh) * 2020-04-13 2025-04-04 阿普塔生物治疗公司 包含吡唑衍生物的肺纤维化药物
KR102386097B1 (ko) * 2020-04-13 2022-04-14 압타바이오 주식회사 피라졸 유도체의 폐섬유증 치료제
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法
KR102589130B1 (ko) * 2021-03-24 2023-10-13 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물
EP4320233A4 (en) 2021-04-07 2025-08-13 Battelle Memorial Institute RAPID DESIGN, BUILD, TEST, AND LEARNING TECHNOLOGIES TO IDENTIFY AND USE NON-VIRAL VECTORS
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
CN119504599B (zh) * 2024-11-18 2025-09-26 安徽医科大学 一种用于治疗肾脏纤维化的吡唑类化合物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292744A (en) * 1990-07-24 1994-03-08 Bayer Aktiengesellschaft 1-[pyri(mi)dyl-(2)]-5-hydroxy-pyrazole microbicides
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
EP2050745A1 (en) * 2006-09-01 2009-04-22 Otsuka Chemical Co., Ltd. N-pyridylpiperidine compound, method for producing the same, and pest control agent
KR100942382B1 (ko) 2008-03-25 2010-02-12 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물
KR20110025151A (ko) 2009-09-02 2011-03-09 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR20110025149A (ko) 2009-09-02 2011-03-09 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2697092A (en) 1991-10-08 1993-05-03 Nippon Soda Co., Ltd. Pyrazole derivative and agrohorticultural bactericide containing same
JP2003098120A (ja) 2001-09-26 2003-04-03 Tokyo Weld Co Ltd 外観検査装置
JP4189850B2 (ja) * 2002-05-20 2008-12-03 味の素株式会社 線維化病変組織修復剤
EP1900728A1 (en) * 2005-05-30 2008-03-19 Genecare Research Institute Co., Ltd Pharmaceutical composition comprising pyrazolone derivative

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292744A (en) * 1990-07-24 1994-03-08 Bayer Aktiengesellschaft 1-[pyri(mi)dyl-(2)]-5-hydroxy-pyrazole microbicides
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
EP2050745A1 (en) * 2006-09-01 2009-04-22 Otsuka Chemical Co., Ltd. N-pyridylpiperidine compound, method for producing the same, and pest control agent
KR100942382B1 (ko) 2008-03-25 2010-02-12 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물
KR20110025151A (ko) 2009-09-02 2011-03-09 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR20110025149A (ko) 2009-09-02 2011-03-09 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Atlas of End-Stage Renal Disease in the United States", 2011, NATIONAL INSTITUTES OF HEALTH
ALMANSA, C. ET AL.: "Synthesis and structure-activity relationship of a new series of potent AT selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, 1997, pages 547 - 558, XP000652306 *
HWANG I; LEE J; PARK J; HUH JY; LEE HB; HO YS; HA H: "Catalase deficiency accelerates diabetic renal injury through peroxisomal dysfunction", DIABETES, vol. 72, 2012, pages 8 - 738
LEE EA; SEO JY; JIANG Z; YU MR; KWON MK; HA H; LEE HB: "Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney", KIDNEY INT., vol. 67, 2005, pages 1762 - 71
NOH H; KIM JS; HAN K-H; LEE GT; SONG JS; CHUNG SH; JEON JS; HA H; LEE HB: "Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane", KIDNEY INT., vol. 69, 2006, pages 2022 - 2028, XP008162013, DOI: doi:10.1038/sj.ki.5001506
QIAN Y; FELDMAN E; PENNATHUR S; KRETZLER M; BROSIUS FC 3RD: "From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy", DIABETES, vol. 57, 2008, pages 1439 - 45
SAWYER, J. S. ET AL.: "Synthesis and activity of new aryl- and heteroaryl- substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 19, 2003, pages 3953 - 3956, XP002265227 *
SCHIEPPATI A; REMUZZI G: "Chronic renal diseases as a public health problem: epidemiology, social, and economic implications", KIDNEY INT, vol. 98, no. 1, 2005, pages S7 - S10
ZHANG MZ; WANG S; YANG S; YANG H; FAN X; TAKAHASHI T; HARRIS RC: "The Role of Blood Pressure and the Renin-Angiotensin System in Development of Diabetic Nephropathy (DN) in eNOS-/- db/db Mice", AM J PHYSIOL RENAL PHYSIOL., 2011

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2754255C2 (ru) * 2017-04-20 2021-08-31 Аптабайо Терапьютикс Инк. Новое кристаллическое твердое соединение гидрохлорида 3-фенил-4-пропил-1-(пиридин-2-ил)-1н-пиразол-5-ола
US11174240B2 (en) 2017-04-20 2021-11-16 Aptabio Therapeutics Inc. Crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride

Also Published As

Publication number Publication date
CN104755077A (zh) 2015-07-01
ES2734264T3 (es) 2019-12-05
JP5974180B2 (ja) 2016-08-23
KR101633957B1 (ko) 2016-06-27
US10047067B2 (en) 2018-08-14
JP2015531774A (ja) 2015-11-05
CN104755077B (zh) 2018-05-15
KR20140027833A (ko) 2014-03-07
EP2889032A1 (en) 2015-07-01
TR201909923T4 (tr) 2019-07-22
EP2889032A4 (en) 2016-03-09
US20150218125A1 (en) 2015-08-06
EP2889032B1 (en) 2019-05-08
PL2889032T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
WO2014035070A1 (ko) 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
CA2735162C (en) Pyrrole compounds
US10766882B2 (en) 1,2-naphthoquinone based derivative and method of preparing the same
WO2011159124A2 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2021145655A1 (ko) 신규한 피라졸 유도체
WO2012118309A2 (ko) 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
WO2012118308A2 (ko) 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물.
WO2014171801A1 (ko) 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 약학조성물
WO2017176040A1 (ko) Ras를 분해하는 이종원자고리화합물 및 이의 용도
JP6625057B2 (ja) Ｒｘｒアゴニストとしての置換二環式ヘテロアリール化合物
US4914099A (en) Hydantoin derivatives as aldose reductase inhibitors
WO2019182276A1 (en) Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin
WO2011049274A1 (en) Imidazole derivatives and compositions for treating melanoma
KR20130032847A (ko) 이미드를 포함하는 벤조싸이아졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
WO2015102282A1 (ko) 안지오텐신-ⅱ 수용체 차단제 및 hmg-coa 환원효소 저해제를 포함하는 약제학적 복합제제
WO2021040257A1 (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
WO2023113458A1 (en) Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof
WO2015115826A1 (ko) 소양증 개선 활성을 갖는 벤즈옥사졸 유도체
WO2020091204A1 (ko) 벤조헤테로사이클 화합물 및 이를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물
WO2020040343A1 (en) Isoxazole derivatives and preparation process thereof
KR102727491B1 (ko) RORα의 활성자로서의 신규한 티오우레아 유도체 및 이를 포함하는 약학적 조성물
WO2011074881A2 (ko) 알레르기 질환 감수성 유전자 발현 억제 물질
WO2018038297A1 (ko) (r)-(1-메틸피롤리딘-3-일)메틸(3'-클로로-4'-플루오로-[1,1'-비페닐]-2-일)카바메이트의 신규염 및 이의 결정형
WO2022260491A1 (ko) 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
WO2022211574A1 (ko) 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13834243

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015529664

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14424771

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2013834243

Country of ref document: EP